ATE138196T1 - Testverfahren für und behandlung von autoimmunkrankheiten - Google Patents
Testverfahren für und behandlung von autoimmunkrankheitenInfo
- Publication number
- ATE138196T1 ATE138196T1 AT90906028T AT90906028T ATE138196T1 AT E138196 T1 ATE138196 T1 AT E138196T1 AT 90906028 T AT90906028 T AT 90906028T AT 90906028 T AT90906028 T AT 90906028T AT E138196 T1 ATE138196 T1 AT E138196T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- autoimmune diseases
- testing
- diseases
- diagnosis
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31949989A | 1989-03-06 | 1989-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE138196T1 true ATE138196T1 (de) | 1996-06-15 |
Family
ID=23242496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT90906028T ATE138196T1 (de) | 1989-03-06 | 1990-03-05 | Testverfahren für und behandlung von autoimmunkrankheiten |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0463114B1 (de) |
JP (1) | JPH04504173A (de) |
AT (1) | ATE138196T1 (de) |
CA (1) | CA2049007A1 (de) |
DE (1) | DE69027025T2 (de) |
FI (1) | FI914160A0 (de) |
IE (1) | IE900786L (de) |
NO (1) | NO913499L (de) |
PT (1) | PT93337B (de) |
WO (1) | WO1990010871A1 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2181677T3 (es) * | 1991-08-23 | 2003-03-01 | Univ Nebraska | Metodo y composiciones utiles en la reprogramacion celular. |
WO1996010091A1 (en) * | 1994-09-29 | 1996-04-04 | Merck & Co., Inc. | A high capacity screen for immunoregulants |
GB9520411D0 (en) * | 1995-10-06 | 1995-12-06 | Wales College Of Medicine | Method of testing |
WO1999048927A1 (en) * | 1998-03-25 | 1999-09-30 | Cornell Research Foundation, Inc. | Methods for designing specific ion channel blockers |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0407399A4 (en) * | 1988-02-03 | 1991-06-19 | Xoma Corporation | Immunosupression with anti-pan t-cell immunotoxin compositions |
EP0397798A4 (en) * | 1988-02-03 | 1991-10-30 | Xoma Corporation | Therapeutic use of anti-t cell immunotoxin for autoimmune diseases |
-
1990
- 1990-03-05 AT AT90906028T patent/ATE138196T1/de active
- 1990-03-05 DE DE69027025T patent/DE69027025T2/de not_active Expired - Fee Related
- 1990-03-05 EP EP90906028A patent/EP0463114B1/de not_active Expired - Lifetime
- 1990-03-05 CA CA002049007A patent/CA2049007A1/en not_active Abandoned
- 1990-03-05 JP JP2505690A patent/JPH04504173A/ja active Pending
- 1990-03-05 WO PCT/US1990/001197 patent/WO1990010871A1/en active IP Right Grant
- 1990-03-05 PT PT93337A patent/PT93337B/pt not_active IP Right Cessation
- 1990-03-06 IE IE900786A patent/IE900786L/xx unknown
-
1991
- 1991-09-03 FI FI914160A patent/FI914160A0/fi not_active Application Discontinuation
- 1991-09-05 NO NO91913499A patent/NO913499L/no unknown
Also Published As
Publication number | Publication date |
---|---|
EP0463114A4 (en) | 1992-01-22 |
NO913499D0 (no) | 1991-09-05 |
NO913499L (no) | 1991-09-05 |
DE69027025T2 (de) | 1996-10-24 |
JPH04504173A (ja) | 1992-07-23 |
PT93337B (pt) | 1997-01-31 |
WO1990010871A1 (en) | 1990-09-20 |
FI914160A0 (fi) | 1991-09-03 |
EP0463114A1 (de) | 1992-01-02 |
PT93337A (pt) | 1990-11-07 |
DE69027025D1 (de) | 1996-06-20 |
CA2049007A1 (en) | 1990-09-07 |
EP0463114B1 (de) | 1996-05-15 |
IE900786L (en) | 1990-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lies et al. | Relative T‐cell specificity of lymphocytotoxins from patients with systemic lupus erythematosus | |
ATE255902T1 (de) | Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv- verwandten krankheiten | |
ES2132063T3 (es) | Procedimiento para la captura y recuperacion de celulas. | |
ATE315654T1 (de) | Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen | |
ES2075050T3 (es) | Peptidos que tienen actividad cooperadora de celulas t. | |
TR199901971T2 (xx) | Bir resept�re ba�lanan peptidler ve bile�ikler. | |
ES2133813T3 (es) | Cadenas de lamininas: diagnostico y uso terapeutico. | |
ATE244299T1 (de) | Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis | |
ATE6032T1 (de) | Biologisch aktive substanzen, deren herstellung aus menschlichem kasein und zubereitungen, die sie enthalten. | |
ES2172287T4 (es) | Metodos de deteccion y tratamiento de individuos con celulas anormales que expresan los antigenos peptidicos hla-a2/tirosinasa. | |
IT8026366A0 (it) | Composizione termostabile formatrice di polimero e suo impiego negli esami diagnostici di sostanze biologiche. | |
ATE138196T1 (de) | Testverfahren für und behandlung von autoimmunkrankheiten | |
CA2070647A1 (en) | Use of an anticoagulant as a diagnostic agent | |
ATE125870T1 (de) | Hiv-spezifische monoklonale antikörper und hybridome zu ihrer herstellung. | |
DE58908628D1 (de) | Mittel für immunchemische Tests, carboxylgruppenhaltige Polymere enthaltend. | |
Hong | Update on the immunodeficiency diseases | |
DE3784468D1 (de) | Testbares mehrmodus-zaehlernetz und methode zur durchfuehrung des tests. | |
ATE178074T1 (de) | Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes | |
WUEPPER et al. | Serologic tests for syphilis and the false-positive reactor | |
BR8700693A (pt) | Expelentes de microbios fitopatogenicos e composicao expelente de microbios fitopatogenicos | |
BG28719A3 (en) | Method of obtaining of 17- alfa- (3- iodinebenzoiloxy)- 9 alfa chloride- 4- pregnen 3,20- dions and their alfa- homoanaloges | |
Nuti et al. | Circulating immune complexes detected by Clq solid phase assay in leprosy | |
Thompson | Sexual Promiscuity | |
Chapman et al. | Do parathyroid and adrenal autoantibodies coexist? | |
Hawley et al. | The effect of divalent cation chelators and magnesium on activation of the alternative complement pathway by Fusobacterium polymorphum (nucleatum) |